
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11428819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections. PLoS ONE, 2022, 17, e0264305.	1.1	2
2	Co-administration of routine paediatric vaccines in England often deviates from the immunisation schedule. Vaccine: X, 2021, 9, 100115.	0.9	2
3	Adherence to the paediatric immunisation schedule in England. Vaccine: X, 2021, 9, 100125.	0.9	3
4	Safety of Co-Administration Versus Separate Administration of the Same Vaccines in Children: A Systematic Literature Review. Vaccines, 2020, 8, 12.	2.1	13
5	Intussusception in children aged under two years in India: Retrospective surveillance at nineteen tertiary care hospitals. Vaccine, 2020, 38, 6849-6857.	1.7	9
6	Acute aseptic arthritis: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2019, 37, 384-391.	1.7	3
7	Arthritis and arthralgia as an adverse event following immunization: A systematic literature review. Vaccine, 2019, 37, 372-383.	1.7	8
8	Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2019, 37, 392-399.	1.7	2
9	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. Journal of Clinical Pharmacology, 2018, 58, S123-S139.	1.0	6
10	Intussusception in Young Children: Protocol for Multisite Hospital Sentinel Surveillance in India. Methods and Protocols, 2018, 1, 11.	0.9	6
11	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. Vaccine, 2018, 36, 6202-6211.	1.7	53
12	Vasculitic peripheral neuropathy: Case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1567-1578.	1.7	37
13	Kawasaki disease and immunisation: A systematic review. Vaccine, 2017, 35, 1770-1779.	1.7	27
14	Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581.	1.7	22
15	lgA vasculitis (Henoch–Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine, 2017, 35, 1559-1566.	1.7	9
16	Safety assessment of immunization in pregnancy. Vaccine, 2017, 35, 6469-6471.	1.7	25
17	Procalcitonin for Diagnostics and Treatment Decisions in Pediatric Lower Respiratory Tract Infections. Frontiers in Pediatrics, 2017, 5, 183.	0.9	13
18	Drivers of antibiotic prescribing in children and adolescents with febrile lower respiratory tract infections. PLoS ONE, 2017, 12, e0185197.	1.1	13

#	Article	IF	CITATIONS
19	Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. Vaccine, 2016, 34, 6007-6014.	1.7	22
20	Global alignment of immunization safety assessment in pregnancy – The GAIA project. Vaccine, 2016, 34, 5993-5997.	1.7	72
21	Global Vaccine Safety Assessment. Pediatric Infectious Disease Journal, 2016, 35, 446-448.	1.1	7
22	Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. Expert Review of Vaccines, 2016, 15, 573-584.	2.0	13
23	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006.	1.7	42
24	Evaluation of a multinational, multilingual vaccine debate on Twitter. Vaccine, 2016, 34, 6166-6171.	1.7	33
25	Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis. Vaccine, 2016, 34, 6582-6596.	1.7	12
26	Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6572-6581.	1.7	4
27	Reference set for performance testing of pediatric vaccine safety signal detection methods and systems. Vaccine, 2016, 34, 6626-6633.	1.7	4
28	Vasculitis as an adverse event following immunization – Systematic literature review. Vaccine, 2016, 34, 6641-6651.	1.7	87
29	Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640.	1.7	41
30	Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine, 2015, 33, 6441-6452.	1.7	37
31	Pediatric Drug Safety Signal Detection: A New Drug–Event Reference Set for Performance Testing of Data-Mining Methods and Systems. Drug Safety, 2015, 38, 207-217.	1.4	19
32	Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. Vaccine, 2015, 33, 5333-5341.	1.7	6
33	A systematic review of adverse events following immunization during pregnancy and the newborn period. Vaccine, 2015, 33, 6453-6465.	1.7	32
34	Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project. PLoS ONE, 2015, 10, e0130399.	1.1	29
35	Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. PLoS ONE, 2014, 9, e82222.	1.1	53
36	International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 2013, 31, 4448-4458.	1.7	91

#	Article	IF	CITATIONS
37	Template protocol for clinical trials investigating vaccines—Focus on safety elements. Vaccine, 2013, 31, 5602-5620.	1.7	17
38	Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower Respiratory Tract Infection in Children and Adolescents (ProPAED): A Randomized Controlled Trial. PLoS ONE, 2013, 8, e68419.	1.1	90
39	A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine, 2012, 30, 3042-3046.	1.7	39
40	Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Biologicals, 2012, 40, 393-397.	0.5	19
41	Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine, 2011, 29, 7559-7571.	1.7	22
42	Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ: British Medical Journal, 2011, 343, d3908-d3908.	2.4	127
43	Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine, 2009, 27, 2289-2297.	1.7	31
44	Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine, 2009, 27, 2282-2288.	1.7	48
45	Interstrain Antigenic Variability of Mumps Viruses. Clinical Infectious Diseases, 2008, 46, 150-151.	2.9	7
46	Three-Year Surveillance of Intussusception in Children in Switzerland. Pediatrics, 2007, 120, 473-480.	1.0	135
47	Adverse events following immunization: perception and evidence. Current Opinion in Infectious Diseases, 2007, 20, 237-246.	1.3	27
48	The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine, 2007, 25, 5671-5674.	1.7	80
49	Update on new vaccines and immunisation strategies. Current Paediatrics, 2006, 16, 1-7.	0.2	0
50	Evaluation of the Brighton Collaboration case definition of acute intussusception during active surveillance. Vaccine, 2006, 24, 1483-1487.	1.7	18
51	Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. European Journal of Pediatrics, 2005, 164, 366-370.	1.3	76
52	Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 586-591.	1.7	19
53	Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 557-562.	1.7	89
54	Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 563-568.	1.7	28

#	Article	IF	CITATIONS
55	The Brighton Collaboration—enhancing vaccine safety. Vaccine, 2004, 22, 2046.	1.7	26
56	Standardized case definitions of adverse events following immunization (AEFI). Vaccine, 2004, 22, 547-550.	1.7	38
57	The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiology and Drug Safety, 2003, 12, 335-340.	0.9	50
58	The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine, 2002, 21, 298-302.	1.7	134